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RESEARCH ARTICLE
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Abstract
Introduction: Intellectual disability, accelerated aging, and early-onset Alzheimer-
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like neurodegeneration are key brain pathological features of Down syndrome (DS).
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Although growing research aims at the identification of molecular pathways underly-
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ing the aging trajectory of DS population, data on infants and adolescents with DS are
missing.
Methods: Neuronal-derived extracellular vesicles (nEVs) were isolated form healthy
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donors (HDs, n = 17) and DS children (n = 18) from 2 to 17 years of age and nEV content
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in pIRS1Ser636 , a marker of insulin resistance, and the hyperactivation of the
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was interrogated for markers of insulin/mTOR pathways.
Results: nEVs isolated from DS children were characterized by a significant increase
Akt/mTOR/p70S6K axis downstream from IRS1, likely driven by the higher inhibition
of Phosphatase and tensin homolog (PTEN). High levels of pGSK3βSer9 were also found.
Conclusions: The alteration of the insulin-signaling/mTOR pathways represents an
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early event in DS brain and likely contributes to the cerebral dysfunction and intellec-
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tual disability observed in this unique population.
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BACKGROUND

The intellectual disability associated with DS likely results from
alterations of brain development that can be traced back to fetal life

Down syndrome (DS) is the most common genetic form of intellectual

stages. These alterations include widespread defects in neurogenesis,

disability, caused by the triplication of chromosome 21 (Hsa21), with

excessive numbers of astrocytes, dendritic atrophy, and impaired

a prevalence of ≈12.8 per 10,000 births (≈1 in 780 newborns).1

connectivity.1,2

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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HIGHLIGHTS

RESEARCH IN CONTEXT

∙ Brain insulin resistance develops early in Down syndrome

1. Systematic review: The authors reviewed the literature

(DS) independent of peripheral alterations.

using PubMed. The increased incidence of metabolic dis-

∙ Brain insulin resistance is associated with mTOR hyperac-

orders in Down syndrome (DS) is documented, and sev-

tivation in DS.
∙ Neuronal-derived extracellular vesicles (nEVs) allow

eral studies have examined metabolites and bioenergetic

detection of alterations of the insulin/mTOR pathway in

vious work. However, there is a substantial lack of evi-

DS brain.

dence on the alteration of insulin and mTOR pathways in

∙ PTEN inhibition drives insulin/mTOR alterations in DS
brain.

defects in the DS population. We have cited all the pre-

DS, particularly in the younger population.
2. Interpretation: This study shows that the analysis of

∙ Alterations of the insulin/mTOR pathway allow discrimi-

nEVs can be used to detect early alterations of the
insulin/mTOR pathway in the brain of young DS individ-

nation of DS versus healthy individuals.

uals. These alterations likely worsen intellectual disability in DS and may favor Alzheimer’s disease (AD) development with age.
Over the last decades, the lifespan of people with DS has significantly extended. However, the increased life expectancy brings about
a higher risk of developing Alzheimer’s disease (AD)–like

dementia.3,4

Due to the triplication of the amyloid precursor protein gene (APP)
on Hsa21, DS may potentially be envisioned as a genetic form of AD,
similar to its autosomal dominant form.3, 4 Therefore, persons with DS

3. Future directions: The evaluation of nEVs content may
be useful to identify novel targets for therapeutic interventions in DS. This aspect will be strengthened by performing additional studies to explore whether alterations
identified through the analysis of nEVs associate with
worse cognitive outcomes in DS.

represent a population to explore the molecular mechanisms underlying intellectual disability as well as neurodegeneration. Several studies have focused on the identification of neuronal pathways involved
in synaptic plasticity, neurogenesis, and neurotransmission, which are
altered early in life in people with DS.3 However, no single gene or

In this regard, plasma-resident neuronal-derived extracellular vesi-

region of Hsa21 has been found to be responsible for all of the common

cles (nEVs) show great potential as a diagnostic tool.17 EVs are a het-

features of DS.5 This suggests that the coordination of multiple genes

erogeneous population of vesicles released into the extracellular space

and other factors may be responsible for the development of major DS

by all cell types, including brain cells for cell-to-cell communication.18

phenotypes.3,6

EVs carry surface markers and biologically active cargo molecules that

Previous studies support the idea that altered insulin signal-

are specific to their originating tissue/cell and that may reflect the tis-

ing in the brain, referred to as brain insulin resistance, may affect

sue/cell’s physiological state.19,20 Thus the isolation of nEVs from the

the molecular pathways involved in synaptic plasticity and adult

blood may provide a minimally invasive approach for sampling neuronal

neurogenesis.7

components in DS and may, therefore, be considered a form of “liquid

Indeed, the development of brain insulin resistance

may lead to a reduction of “mindspan”—the ability of the brain to

biopsy.”20

preserve mental capabilities throughout life—and increase the risk of

Recently, the characterization of nEVs cargo provided valu-

neurodegeneration.8 The mammalian target of rapamycin (mTOR) is

able information on the molecular alterations underlying AD

a “master switch” between anabolic and catabolic cellular processes9

neuropathology.17,21 Increased levels of AD biomarkers, such as

through regulating glucose metabolism, bioenergetics, mitochondrial

amyloid beta (Aβ) and phosphorylated tau (p-tau), were observed in

function, and autophagy, also in response to insulin.10,11 mTOR has

nEVs from persons with AD relative to controls.22,23 Furthermore, the

also been involved in long-lasting synaptic adaptations at the basis of

analysis of nEVs collected from participants of the Baltimore Longitu-

higher-order brain function (ie, synaptic plasticity, memory preserva-

dinal Study of Aging revealed that markers of brain insulin resistance

tion, and neuronal recovery).10 Previous studies by our group and by

were among the strongest individual predictors of AD development,

others indicate that both insulin and mTOR signaling pathways are

thereby highlighting a role for altered insulin signaling in AD onset

impaired early in life in the brain of people with DS12,13 and DS animal

and progression.17 In addition, high levels of Aβ1-42, pTau181, and

models.14–16 Moreover, crosstalk between insulin signaling and mTOR

p-s396-Tau were identified in the nEVs of persons with DS compared

pathway has been indicated to play a key role in the maintenance of

with age-matched controls, already in childhood.24

mindspan. Therefore, understanding at which time point and through

Although a role for insulin/mTOR pathway during brain develop-

which trajectory the disturbance of the insulin/mTOR pathway occurs

ment and in the maintenance of brain functions has been proposed,

and persists may indicate therapeutic targets against intellectual dis-

no evidence is available in children with DS. In the present study, we

ability and neurodegeneration in people with DS.

applied a multiplex immunoassay for the simultaneous evaluation of all

3

PERLUIGI ET AL .

the mediators of the insulin/mTOR pathway in circulating nEVs isolated
from infants and adolescents with DS and age-matched controls.

2
2.1

TA B L E 1 Demographic and anthropometric characteristics of
controls (HD) and children with Down syndrome (DS)

N

METHODS
Study participants

HD

DS

P

17

18

.81

Age range

4 – 17 years

2 – 16 years

Age distribution (n)

0 – 5 years: 5

0 – 5 years: 8

For the present study, we enrolled infants and adolescents with DS

6 – 11 years: 8

6 – 11 years: 4

12 – 17years: 4

12 – 17 years: 6

8.6 ± 4.4

8.7 ± 5.2

(n = 18) and age-matched healthy donors (HDs, n = 17) from the

Age (mean ± SD)

Down Syndrome and Pediatric Outpatient Clinic of the Bambino Gesù

Sex (M/F)

9/8

10/8

.88

Children’s Hospital in Rome (Italy). The study was approved by the

Weight (mean, kg ± SD)

31.3 ± 16.2

30.2 ± 21.3

.33

ethics committee of the Bambino Gesù Children Hospital (protocol

Fasting glycemia (mean,
mg/dL ± SD)

68.9 ± 12.7

64.6 ± 9.8

.16

Fasting insulin (mean,
μU/mL ± SD)

8.9 ± 7.3

8.5 ± 4.5

.79

included. Consent for inclusion in the study was obtained during a visit
to outpatient clinics from all participants.

HOMA-IR

1.52 ± 1.08

1.50 ± 0.92

.95

18.7 ± 5.2

19.8 ± 4.5

.18

Centile (mean ± SD)

59.8 ± 29.9

46.11 ± 25.5

.21

Obesity (n)

3

0

.06

ID # 1771_OPBG_2019). We have received and archived written consent for participation/publication from every individual whose data are

BMI (kg/m , mean ± SD)
2

2.2

nEV isolation

Blood samples were obtained from all participants after overnight
fasting. All blood draws and processing followed established protocols using standard venipuncture procedures. Blood was collected in
ethylenediaminetetraacetic acid (EDTA) polypropylene tubes, and was

.68

Overweight (n)

3

1

.26

NAFLD (n)

0

0

n.s.

BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin
resistance; NAFLD, non-alcoholic fatty liver disease

centrifuged at 850×g for 15 minutes at 4◦ C. Afterward, plasma was
isolated and centrifuged again at 850×g for 15 minutes at 4◦ C to
eliminate clots and aggregates. Plasma samples were then divided
−80◦ C

tion at 800×g for 10 minutes at 4◦ C and removal of supernatant, nEVs

until analysis. Preanalyt-

were eluted with 200 μL of 0.1 M glycine. Beads were then sedimented

ical factors for blood collection and storage complied with guide-

by centrifugation at 4500×g for 5 minutes at 4◦ C, and the supernatants

lines for EV biomarkers.18 Evaluation of fasting glycemia and insu-

containing nEVs were transferred to clean tubes. pH was neutralized

linemia (Table 1) was performed on the same plasma samples used

with 1 M Tris-HCl, and samples underwent two freeze/thaw cycles

to isolate nEVs. Homeostatic model assessment for insulin resistance

with M-PER protein extraction reagent (Thermo Scientific, Inc.) sup-

(HOMA-IR) (Table 1) was then calculated by using the following for-

plemented with protease and phosphatase inhibitors. The final suspen-

mula: (fasting plasma insulin in mU/L × fasting plasma glucose in

sions containing nEVs proteins were stored at −80◦ C. Samples were

mmol/L)/22.5. nEV isolation was performed as described previously,

thawed and vortexed twice prior to protein measurements. The stored

with minor modifications.17,25 Plasma samples were thawed on ice

suspensions were used to determine the total protein concentration

and defibrinated with thrombin (System Biosciences, Inc., Mountain-

by the Bradford assay (Pierce, Rockford, IL, USA). All investigators

view, CA) followed by 30 minutes of incubation at room temperature.

involved in nEV isolation and biomarker quantification were blinded

Two-hundred fifty microliters of plasma were diluted 1:1 v/v with Dul-

until all measurements were completed.

into 0.5-mL aliquots and stored at

becco’s calcium and magnesium-free salt solution (DSB, Thermo Scientific, Inc., Waltham, MA) with the addition of protease (#P8340, Sigma–
Aldrich, St Louis, MO, USA) and phosphatase inhibitors (#P5726,
Sigma–Aldrich, St Louis, MO, USA). Total EVs were collected using an

2.3
nEVs characterization by dynamic light
scattering

Exo-spin Blood kit EX-02 (Cell Guidance, Cambridge, UK) according to
the manufacturer’s instructions, and finally resuspended in 0.5 mL of

Ten microliters of intact nEVs were used for the determination of the

ultra-pure distilled water with the manufacturer-recommended con-

vesicle hydrodynamic diameter through dynamic light scattering (DLS).

centration of protease and phosphatase inhibitors. To immunocapture

The mean hydrodynamic diameter (Z-average size), size distribution,

L1 cell adhesion molecule (L1CAM)–positive nEVs, the suspension was

and correlation curve of nEVs in phosphate-buffered saline (PBS; pH

incubated for 1 hour at 4◦ C with 4 μg of mouse anti-human CD171

7.2, dilution factor 1:100) were measured at 25◦ C using a Zetasizer

(L1CAM) biotinylated antibody (clone 5G3) (Thermo Scientific, Inc.),

Pro (Malvern Panalytical, UK) equipped with a solid state HeNe laser

followed by incubation with 25 μL of Pierce Streptavidin Plus UltraLink

(λ = 632.8 nm) at the scattering angles of 173◦ and 13◦ . Size measure-

Resin (Thermo Scientific, Inc.) for 30 minutes at

4◦ C.

After centrifuga-

ment data were analyzed by the general-purpose algorithm.

4
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2.4
nEV characterization by transmission electron
microscopy

immunoprecipitated with an antibody targeting the N-terminal region

Intact nEVs were used for morphological evaluation of nEVs. The puri-

for 60 minutes at room temperature with the appropriate secondary

fied suspension stored at 4◦ C was deposited by drop casting on a For-

antibodies conjugated with horseradish peroxidase (1:5000; Sigma–

mvar copper grid and subsequently stained by Uranyless solution for

Aldrich, St. Louis, MO, USA). Membranes were developed with Clarity

1 minute. Transmission electron microscopy (TEM) observations were

enhanced chemiluminescence (ECL) substrate (Bio-Rad Laboratories,

performed using a Zeiss EM10 (Zeiss, Oberkochen, Germany) at 60 kV.

#1705061), and the signal was acquired with Chemi-Doc MP (Bio-Rad

(5G3).
After three washes with TBS-t buffer, membranes were incubated

Laboratories) and analyzed using Image Lab software (Bio-Rad Laboratories). Normalization was performed against total protein load signal.

2.5
nEVs characterization for EVs and neuronal
markers
2.7

Bioplex assay

The detection of both transmembrane and intravesicular EV markers
is required to confirm the sequential enrichment of EVs from neat

A magnetic bead–based immunoassay was used to measure levels

plasma using Exo-spin Blood kit EX-02 sedimentation of total EVs fol-

of eight phosphoproteins and total target proteins pertaining to the

lowed by immunoprecipitation of nEVs. EV enrichment was confirmed

mTOR signaling pathway in nEVs. All mediators were assayed in mul-

by showing the presence of transmembrane (cluster of differentiation

tiplex using the Bio-Plex Pro Cell Signaling protein kinase B (Akt) Panel,

81, CD81) and intravesicular EV markers (Alix) as well as the relative

8-plex (Bio-Rad Laboratories, #LQ00006JK0K0RR) to measure levels

depletion of lipoprotein (apolipoprotein A1, APOA1) in both total and

of the following phosphorylated proteins: insulin receptor substrate-

nEVs compared with EV-depleted plasma. Moreover, enrichment of

1 at Ser363 (pIRS1Ser636 ), phosphatase and tensin homolog at Ser380

EVs of neuronal origin was confirmed by evaluating L1CAM and neu-

(Phosphatase and tensin homolog (pPTEN)Ser380 ), serine/threonine-

ronal nuclear protein (NeuN) levels, as neuronal markers, in nEVs, total

protein kinase Akt-1 at Ser 473 (pAktSer473 ), glycogen synthase kinase-

EVs, and EV-depleted plasma samples. The evaluation of the markers

3β at Ser9 (pGSK3βSer9 ), mTOR at Ser2448 (pmTORSer2448 ), p70 S6

mentioned above was performed by Western blot analysis described

kinase at Thr389 (p70 S6 Kinase (pP70S6K)Thr389 ), ribosomal pro-

below.

tein S6 kinase beta-1 at Ser235/236 (pS6Ser235/Ser236 ), and the Bcl2associated agonist of cell death at Ser136 (pBADSer136 ). Experiments
were run on a Bio-Plex System with Luminex xMAP Technology (Bio-

2.6

Western blot analysis

Rad Laboratories) and data were acquired on a Bio-Plex Manager
Software 6.1 (Bio-Rad Laboratories) with instrument default settings.

Ten micrograms of proteins for each sample were resolved on Crite-

Median fluorescence intensities (MFI) corrected for the blank back-

rion TGX Stain-Free 4-15% 18-well gel (Bio-Rad Laboratories, Her-

ground were obtained for all analytes and results were calculated as

cules, CA, USA; #5678084) in a Criterion large format electrophoresis

the ratio between the MFI of phosphorylated targets and total pro-

cell (Bio-Rad Laboratories, #1656001) in Tris/Glycine/SDS (TGS) Run-

teins.

ning Buffer (Bio-Rad Laboratories, #1610772). Immediately afterward,
the gel was placed on a Chemi/UV/Stain-Free tray and visualized using
a ChemiDoc MP imaging System (Bio-Rad Laboratories, #17001402) in

2.8

Statistical analyses

a UV setting. Total protein load was assessed using the Image Lab Software (Bio-Rad Laboratories).

Data were first tested for equal variance and normality (Shapiro-Wilk

Subsequently, proteins were transferred via a TransBlot Turbo

test). Data were not normally distributed and, therefore, the nonpara-

semi-dry blotting apparatus (Bio-Rad Laboratories, #1704150) onto

metric Mann-Whitney test was used to compare participants with DS

nitrocellulose membranes (Bio-Rad laboratories, #162-0115). Mem-

and healthy donors. A two-tailed alpha value of 0.05 was used to

branes were blocked with 3% bovine serum albumin in 0.5% Tween-

denote statistical significance.

20/Tris-buffered saline (TBS-t) and incubated overnight at 4◦ C with the

Correlations were estimated by the Spearman test. Multivariate sta-

following antibodies: anti-CD81 (1:1000, Cell Signaling, Bioconcept,

tistical modeling was then used to differentiate participants with DS

Allschwill, Switzerland, #56039S), anti-Alix (1:1000, Cell Signaling,

and healthy donors based on levels of the measured mediators. A one-

Bioconcept, #2171S), anti-L1CAM (1:1000, Cell Signaling, #89861S),

class classification strategy (also known as class-modeling), based on

anti-APOA1 (1:2000, Thermo Scientific, Inc., #LF-MA0127), anti-NeuN

the use of the soft independent modeling of class analogies (SIMCA)

(1:1000, Thermo Scientific, Inc., #702022), anti-Syntaxin-1A (1:1000,

method, was adopted.26 SIMCA is particularly suitable for defining the

GeneTex, Irvine, CA, USA; #GTX113559), anti-PSD95 (1:1000, Cell

salient traits of a target category, enabling one to verify whether new

Signalling, #3450S), and anti-phospho-CaMK IIα Thr286 (1:1000, Cell

individuals are likely to belong to that same category or not. Mathemat-

Signaling, #12716S). For L1CAM detection, an antibody targeting

ically, it operates by calculating a principal component (PC) model of

the C-terminal region of the protein was used, while nEVs were

the category of interest (in the present case, healthy donor group), and

5
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F I G U R E 1 Characterization of the plasma-resident neuronal-derived extracellular vesicles (nEVs).. (A) Total protein content, (B) size
distribution, (C) correlation curve, and (D) Z-average size (nm) of nEVs isolated from healthy donors (HDs) and participants with Down syndrome
(DS). Error bars represent standard deviation (SD). In (E-F), morphological study of nEVs. BF-TEM image of nEVs (E). Plot showing the frequency
distribution of the vesicle size histogram (F). Data fit by Gaussian convolution functions (red line). P < .01 statistically significant difference
between experimental and theoretical data fitting. Furthermore, identification of nEV membranes evidences the presence of the bilayer
membranes (inset in F). In (G), representative Western blot images of total EVs (T, isolated with Exo-spin Blood kit EX-02), EV-depleted plasma (P,
supernatant after Exo-spin Blood kit EX-02), and nEVs (after immunocapture with L1CAM) isolated from HD (n = 3) and DS (n = 3) and probed for
L1CAM, NeuN, Alix, CD81, and APOA1. The two bands detected for L1CAM in nEVs represent the non-glycosylated (∼≈170 kDa) and the
glycosylated form (∼≈220 kDa). In (H), the degree of neuronal enrichment for nEVs compared to total EVs. L1CAM and NeuN and CD81
densitometric values were first normalized for total load and then both L1CAM and NeuN levels were expressed as a ratio with CD81. Data are
presented as means ± SD. *P < .05 versus Total EVs (Mann-Whitney)

testing each new observation for its degree of deviation with respect

3

RESULTS

to that model. Specifically, for each individual, a distance to the class
model d is calculated as the combination of two test statistics, namely

3.1

Demographics and clinical characteristics

T2 , which accounts for the Mahalanobis distance of the sample’s score
to the center of the PC space, and Q, which corresponds to the squared

Thirty-five participants ranging in age between 2 and 17 years, includ-

residuals (ie, the squared Euclidean distance of the observation from

ing 18 with DS and 17 controls, were enrolled and included in the anal-

its PC analysis projection). To make the two terms comparable, prior to

ysis. Baseline characteristics of participants are listed in Table 1. Partic-

being combined into the overall distance to the model, they are normal-

ipants with and without DS did not differ for any demographic, clinical,

ized by division to their critical value at 95% confidence. Accordingly,

or anthropometric characteristics.

verification of whether an individual is likely to be part of the healthy
donor class or not is based on assessing if the distance to the model is
below a predefined criterion. In mathematical terms:
√
di =

(

Ti,2 norm

)2

+ Q2i, norm ≤

√
2

i indicating the generic ith individual and the subscript norm explicitly
referring to the above-mentioned normalization.

3.2

Characterization of nEVs

nEV preparations were characterized for protein content, size, and
morphology through DLS and TEM, along with immunoblotting analyses for positive and negative EV markers, according to established
criteria18 (Figure 1).

6
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Quantification of the nEVs was performed by measuring the total

To evaluate whether alterations of the insulin/mTOR pathway were

amount.18,27

associated with synaptic defects in DS, levels of the three main synap-

Higher nEV levels were observed in participants with DS relative to

tic proteins, that is, Syntaxin-1A (pre-synaptic), PSD95 (post-synaptic),

controls (P = .004) (Figure 1A).

and the active form of CamK IIα (pCamK IIαThr286 , a central regu-

protein content, which provides an estimation of nEV

The size distribution of nEVs immunocaptured by L1CAM was stud-

lator of neuronal plasticity30 ), were evaluated. No significant differ-

ied with DLS (Figure 1A and 1B). Correlation coefficients of nEVs from

ences were observed for Syntaxin-1A (1 A.U. vs 0.77 A.U., P = .50),

and so

PSD95 (1 A.U. vs 0.98 A.U., P = .57), or pCamK IIαThr286 levels (1

were mean hydrodynamic diameter values (204 ± 95 nm and 210 ±

A.U. vs 1.07 A.U., P = .46) between DS and controls (Supplementary

96 nm, in controls and participants with DS, respectively) (Figure 1C).

Figure 2).

both participant groups were consistent with EVs

guidelines18

The size of nEVs was comparable between the groups (P = .77).
Bright-field (BF) image TEM showed well-separated nEVs (Fig-

We also evaluated the levels of CD81 and L1CAM in nEVs and
found no significant differences between participant groups (Supple-

ure 1D). Imaging analyses were performed to accurately measure nEV

mentary Figure 3). To further confirm our results, we normalized

size at low magnification to conduct the appropriate statistics.28,29

insulin/mTOR pathway markers levels as well as those of synaptic pro-

Quantitative morphometric measurements were performed by gener-

teins for both CD81 and L1CAM levels, as in previous reports.18,31 Dif-

ating a 2D contour map of 419 vesicles distributed on a probed area

ferences observed between DS and control participants remained sig-

of 6220 nm per 4587 nm (Figure 1D). The analyzed size was plotted

nificant after CD81 or L1CAM normalization (Supplementary Figures

in a frequency profile of EVs with spherical shape. The bin distribu-

3 - 5).

tions were processed by Gaussian fitting, and the frequency distribu-

Taking advantage from the multiplexing property of the Luminex

tion of isolated nEVs was estimated to be centered around the mean

platform, we explored whether activation/inhibition of the above-

value of 64 ± 0.71 nm, having a lowest polydispersity of about 1.10%

mentioned mediators was consistent along the pathway. To this

(Figure 1E). Furthermore, small populations of bins were fitted to esti-

aim, correlation analyses were performed among nEV markers from

mate a mean size of 128 ± 0.51 nm of the nEVs (Figure 1E). It should be

both participant groups. Our findings show that nEV biomarkers

noted that the mean hydrodynamic diameter of nEVs (detected by DLS

are positively and significantly associated with one another in both

measurements) was almost 3-fold greater than the size estimated with

participant groups, except for pmTORSer2448 versus pPTENSer380

TEM, evidencing how the particle behaves in a fluid, thus taking into

(P = .1) and pmTORSer2448 versus pBADSer136 (P = .1) in partici-

account the electric dipole layer that adheres to the vesicle surface.

pants with DS (Figures 3A-D). In addition, a strong negative asso-

The purification of nEVs was confirmed by Western blot anal-

ciation was found between pCamK IIαThr286 and both pAktSer243

ysis showing enrichment for transmembrane and intravesicular EV

and pmTORSer2448 in controls but not in participants with DS

markers (ie, CD81 and Alix) and relative depletion of lipoprotein (ie,

(Figures 3A-D).

APOA1) in total EVs and nEVs compared with EV-depleted plasma
(Figure 1F). A significant increase in neuronal markers levels, that is,
L1CAM (nEVs/total EVs = 2.46) and NeuN (nEVs/total EVs = 1.67), in
nEVs compared with total EVs and EV-depleted plasma confirmed the

3.4
nEV biomarker comparison between
participants with DS and controls according to age

enrichment of nEVs by L1CAM immunoprecipitation (Figure 1G). The
degree of neuronal enrichment is in line with previous studies reporting

To verify whether the observed changes varied according to age, cor-

enrichment values from 1.6-fold to 5.6-fold depending on the marker.20

relation analyses were performed. No significant associations with

In addition, the evaluation of the eluate from the L1CAM immunocap-

age were observed in either participant group (Figures 3A-D). Based

ture of nEVs further reveals that nEVs are enriched in L1CAM and

on that, to unravel whether alterations in DS occur in childhood and

NeuN, whereas EV markers, that is, CD81 and Alix, can be observed in

remain consistent in older children and in adolescents independent of

both nEVs and non-neuronal EVs (Supplementary Figure 1).

age, participants were categorized according to the age range reported
in Table 1. Although differences were evident between DS and controls, the small sample size of each sub-group did not allow us to per-

3.3
nEV biomarker comparison between
participants with DS and controls

form a reliable statistical analysis (data not shown). Hence, participant
age was then categorized according to the median value (7 years for
DS; 8 years for controls), and significantly higher levels of pIRS1Ser636

The interrogation of nEVs for markers of the insulin/mTOR pathway

(0.57 A.U. vs 0.08 A.U., P = .041), pGSK3βSer9 (0.024 A.U. vs 0.009

revealed higher levels of pIRS1Ser636

(0.58 arbitrary units (A.U.) vs 0.23

A.U., P = .02), pmTORSer2448 (0.69 A.U. vs 0.037 A.U., P = .01), and

A.U, P = .041), pPTENSer380 (0.48 A.U. vs 0.19 A.U, P = .015), pAktSer473

pS6Ser235/Ser236 (0.06 A.U. vs 0.01 A.U., P = .04) were observed in par-

(0.15 A.U. vs 0.048 A.U, P = .026),

pGSK3βSer9

(0.036 A.U. vs 0.013

ticipants with DS below the median age relative to their control peers

A.U, P = .017), pmTORSer2448 (0.055 A.U. vs 0.033 A.U, P = .002);

(Figures 4A and 4C). A similar pattern was observed in participants

pP70S6KThr389 (0.21 A.U. vs 0.07 A.U, P = .03), pS6Ser235/Ser236 (0.075

above the median age, although differences did not reach statistical sig-

A.U. vs 0.019 A.U, P = .02), pBADSer136 (0.55 A.U. vs 0.24 A.U, P = .03)

nificance (Figure 4B). No significant differences were observed for any

in participants with DS relative to controls (Figures 2B-I).

synaptic proteins (Supplementary Figure 6).
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F I G U R E 2 nEV biomarker levels in healthy donors (HDs) and children with Down syndrome (DS). (A) Schematic representation of the
insulin/mTOR pathway. Arrows: activation; lines: inhibition; green circles: phosphorylation sites associated with protein activation; red circles:
inhibitory phosphorylation sites. (B-I) Levels of biomarkers of the insulin/mTOR pathway evaluated in nEVs isolated from HD (n = 17) and DS
(n = 18) children. Data are presented as means ± SD. *P < .05 and ** P < .01 versus HD (Mann-Whitney)

3.5

SIMCA analysis

donor class suggests that in our DS population there are higher levels
of pAktSer473 , pBADSer136 , pmTORSer2448 , pPTENSer380 .

The whole set of measured mediator signals was used to build a mul-

Finally, a principal component analysis (PCA) was conducted to

tivariate classification model, with the aim of evaluating whether they

exclude that extreme values observed in DS population were outliers

could provide a differentiation between controls and participants with

and thus can be kept in all the analyses (Supplementary Figure 7). PCA

DS. Through the use of the SIMCA method, a model of the healthy

confirmed that extreme values are not outliers and likely account for

donor class was built and cross-validated, and it was verified whether

the wide variability of pathological phenotypes of DS individuals that

the model could recognize control individuals as part of the category

present with variable severity of clinical features1,3 .

(sensitivity) and DS participants as not (specificity). The optimal complexity of the PC model for the healthy donor class, after auto-scaling
data pre-treatment, was found to be two components. Based on the
model, it was possible to calculate the values of

2
Tnorm

4

DISCUSSION

and Qnorm for

each control and DS participant and, consequently, their distances to

Our work reports for the first time a significant alteration of the

the category model. These results can be graphically visualized in Fig-

insulin/mTOR pathway in infants and adolescents with DS through the

ure 5, where the cross-validated projections of controls and partici-

analysis of nEVs. Furthermore, our data show that changes in the lev-

pants with DS onto the healthy donors model space are displayed. In

els of protein phosphorylation are consistent across adjacent kinases

the plot, the dashed black line corresponds to the decision threshold
√
d ≤ 2. In the calibration phase, the model was able to correctly recog-

of the insulin/mTOR pathway, indicating that the integrity of the sig-

nize as healthy donors all control participants, corresponding to 100%

to investigate the neuronal insulin/mTOR pathway through a minimally

sensitivity, while 2 of the 18 participants with DS were incorrectly

invasive approach.

naling cascade is maintained in nEVs. Hence, nEVs are a valuable tool

accepted by the healthy donor class model, corresponding to a speci-

The first striking finding of our study is the significant IRS1 inhibi-

ficity of 88.9%. In cross-validation, 87.5% sensitivity and 85.4% speci-

tion observed in nEVs from participants with DS. Inhibition of IRS1 is

ficity were obtained, as observable in Figure 5. The inspection of contri-

a marker of brain insulin resistance.7 From a molecular point of view,

2
butions of the individual variables to the value of Tnorm
and Qnorm 32 of

IRS1Ser636 phosphorylation is responsible for the uncoupling between

participants with DS correctly identified as not belonging to the healthy

insulin receptor (IR) and IRS1, which results in the inability of insulin

8
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F I G U R E 3 Correlation analyses in healthy donor (HD) and Down syndrome (DS) groups. Spearman correlation analyses were performed
separately in HD (A-B) and DS groups (C-D) to explore associations among the biomarkers measured in nEVs as well as between biomarker levels
and demographic characteristics of participants. Blue/white/red colors were used for the scheme. Blue represents the highest values, white the
middle, and red the lower values both for Spearman r (A and C) and P values (B and D)

to activate the intracellular pathways downstream of IRS1.11 Brain

ing aberrant mTOR signaling in post-mortem brain from people with

insulin resistance mediates synaptotoxic effects and leads to (1) synap-

DS, with and without AD, and in AD brain.12,37 Hyperactivation of

tic loss, impaired autophagy, and increased neuronal apoptosis7,8,33 ;

mTOR has been associated with defects of autophagosome formation

(2) increased production and secretion of Aβ
increased tau phosphorylation.7,35,36

peptides7,34 ;

and (3)

and autophagy and with accumulation of AD pathology markers.1.2,14

Of interest, all of the above-cited

Accordingly, published data show defects in endo-lysosomal pathways

neuropathological alterations have been described in the brain of adult

in DS38–40 and efficacy of mTOR inhibitors to rescue this abnormality

people with DS (reviewed in3 ). Moreover, these observations are in

in primary fibroblast from persons with DS.41 A protective role for EVs

keeping with clinical studies showing that the failure in brain energy

was previously proposed in DS by showing that higher EV release may

metabolism responsible for cognitive decline during aging or AD could

be a mechanism to alleviate endo-lysosomal dysfunctions both in mice

be driven by the development of brain insulin resistance, particularly at

and humans.27,42 Enhanced EVs secretion,27,31,42 as observed also in

early stages.7,22

our work, might serve as a delayed cellular response to reduce the

In addition, IRS1 inhibition within the brain seems to occur inde-

size and number of endosomal compartments in DS by shedding more

pendent of peripheral alterations. Fasting glycemia, insulinemia, and

endosomal content into the brain extracellular space.27,42 However, it

HOMA-IR—known to represent powerful risk factors for the develop-

is important to highlight that, in addition to the mean of increased nEVs

ment of brain insulin resistance and cognitive decline7 —were within

release in DS, the analysis of nEV content provides information about

normal ranges and did not differ between participants with DS and

the molecular alterations occurring within the brain, as we observed for

controls. Similarly, metabolic disturbances/diseases associated with

the insulin/mTOR pathway, thus representing a powerful tool of inves-

peripheral insulin resistance, such as overweight, obesity, type 2 dia-

tigation.

betes, and non-alcoholic fatty liver disease, were not prevalent in our
participant cohort.

mTOR is involved in neuronal development and proper functioning
of mature neurons,43 and changes in mTOR activity are often observed

Despite IRS1 inhibition, we observed that the activation of Akt,

in neurological diseases, including genetic disorders (eg, tuberous scle-

mTOR, and mTOR-associated targets, that is, P70S6K and S6, was con-

rosis and fragile X syndrome), epilepsy, brain tumors, and neurodegen-

sistently increased in nEVs isolated from participants with DS com-

erative disorders (AD, Parkinson disease, and Huntington disease).44

pared with controls, thus indicating an overactivated state. This obser-

The analysis of nEVs in children with DS, although at a different age,

vation confirms previous studies from ours and other groups show-

recapitulates the main findings obtained from post-mortem brain of

9
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F I G U R E 4 nEV biomarker levels in healthy donors (HDs) and children with Down syndrome (DS) by age category. (A) Levels of biomarkers
for the insulin/mTOR pathway evaluated in nEVs isolated from HD and DS children were expressed by dividing the two groups into two further
sub-groups according to the median age. Median age for HD was 8 years, while for DS children was 7 years. (B-C) Data of the two subgroups above
the median age (HD = 9, DS = 9) are shown in (B), while those of the two subgroups below the median age (HD = 8, DS = 9) are shown in (C). Data
are presented as means ± SD. *P < .05 versus HD (Mann-Whitney)

people with DS.12,45 This is in line with our previous findings and fur-

versely, mTOR activation leads to CaMK IIα inhibition through a feed-

ther confirms the reliability of shuttling EVs as a source of disease

back mechanism, thus contributing to CamK IIα regulation.30 Both

biomarkers.

hyperactivation and sustained inhibition of CaMK IIα are detrimental

Not surprisingly, the hyperactivation of mTOR/P70S6K axis may

to neurons and synaptic plasticity.51 Hence, the lack of correlations

be responsible for the observed IRS1 inhibition in DS, similar to what

that we found in DS suggest that crosstalk between the insulin/mTOR

was reported for AD.37,46,47 Although this feedback loop is intrinsic

pathway and CaMK IIα may be disrupted in DS, which might contribute

to the physiology of insulin signaling, considering that mTOR/P70S6K

to intellectual disability.

dampens excessive IRS1 activation,11 a chronic hyper-activation is

Hyperactivation of the Akt/mTOR axis might also be responsible for

detrimental.11 Within this picture, a role for increased Aβ levels may

increased BAD phosphorylation observed in nEVs isolated from partic-

also be suggested, since Aβ oligomers were demonstrated to both pro-

ipants with DS. Indeed, both Akt and P70S6K are known to phosphory-

mote IRS1 inhibition48

in AD. Thus aber-

late BAD to promote anti-apoptotic signals and, thus, cell survival.52,53

rant, chronic mTOR hyperactivation diverts the feedback mechanism

This is the first observation of increased BAD inhibition in DS and is in

into reduced insulin sensitivity and leads to a harmful synergistic path

agreement with the concept that compensatory events promote sur-

affecting neuronal functions in DS.10

vival mechanisms prior to the development of AD pathology both in

and mTOR hyperactivation49

In addition to that, the hyperactivation of Akt/mTOR axis may con-

persons with DS and transgenic mice.54–56 Moreover, we previously

tribute to dysfunctional synaptic plasticity mechanisms in DS through

reported that pro-apoptotic signals were significantly increased in per-

CaMK IIα. CaMK IIα is a central regulator of neuronal plasticity and

sons with DS only after the development of AD pathology.57

cognitive functions, such as learning.30

Both insulin and nutrients pro-

In the search for putative candidates responsible for the impair-

mote a transient increase of intracellular Ca2+ levels (that activates

ment of insulin/mTOR pathway crosstalk, we suggest that PTEN may

CamK IIα) along with the activation of the Akt/mTOR axis.30,50 Con-

play a role. PTEN is a widely known negative regulator of insulin/PI3K

10
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F I G U R E 5 SIMCA model: cross-validated projection of the samples onto the space of the healthy donor (HD) category. In the space spanned
2
and Qnorm , the region associated with the class HD is represented by the area below the dashed black line identifying the
by the two variables Tnorm
classification threshold. The plot shows that almost all HD participants (blue circles), falling below the line, are correctly identified as members of
the class. Likewise, the majority of participants with DS (red circles), falling above the decision line, are correctly identified as not being HD

signaling.58,59 We hypothesize that the significant PTEN inhibition

population still poorly characterized. As discussed earlier, defects of

(pPTENSer380 )

observed in nEVs from participants with DS would lead

insulin/mTOR pathway, besides being involved in cognitive dysfunc-

to an accumulation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3),

tions, are associated with the onset of AD. The pathophysiology of AD

responsible for sustained overactivation of Akt and its downstream

in DS is similar to that of the sporadic and autosomal dominant forms

targets, that is, mTOR. A dysregulation of the axis is also supported

of AD (reviewed in61 ). Although longitudinal studies of AD in people

by the lack of a significant association between PTEN and either

with DS exist,62 the natural history of biomarker changes in DS has not

mTORSer2448

in participants with DS, but not in controls,

been established except that in the adult population.4 Hence, we pro-

as well as by SIMCA results, suggesting that PTEN inhibition may pro-

pose that the analysis of nEVs may lead to the identification of novel

mote an unchecked Akt hyperactivation, which further contributes to

disease biomarkers early in life that may also become targets for ther-

aberrant mTOR activation and BAD inhibition. This proposed scenario

apeutic development in DS.

or BADSer136

is reinforced by recent observations showing that PTEN inhibition is
coupled with Akt/mTOR hyperactivation in post-mortem brain samples
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